)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Anixa Biosciences
Anixa Biosciences (ANIX) investor relations material
Anixa Biosciences H.C. Wainwright 28th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 28th Annual Global Investment Conference summary11 Sep, 2026
Financial position and business strategy
Maintains a strong balance sheet with $14 million in cash, no debt, and a clean capital structure as of April 30th.
Annual cash burn is low at $5–7 million, supported by partnerships with leading institutions.
Consistent insider buying, including over $2.5 million in open market purchases by leadership.
Leverages partnerships with Cleveland Clinic and Moffitt Cancer Center to minimize overhead.
Plans to out-license programs to pharmaceutical companies for commercialization.
Clinical pipeline and innovation
Two clinical-stage programs: CAR-T therapy for ovarian cancer and a breast cancer vaccine.
CAR-T therapy targets recurrent, resistant ovarian cancer and is in phase I at Moffitt Cancer Center.
Breast cancer vaccine, partnered with Cleveland Clinic and funded by the U.S. Department of Defense, completed phase I and is preparing for phase II.
Both programs show promising clinical data and address large oncology markets.
CAR-T therapy for ovarian cancer
Utilizes engineered T-cells targeting the follicle-stimulating hormone receptor, expressed mainly on ovaries and tumor vasculature.
Direct peritoneal delivery enhances targeting and reduces systemic side effects.
Demonstrated improved survival in heavily pretreated patients, with some exceeding expected survival by over two years.
Ongoing dose escalation with 14 patients treated and further cohorts planned.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Anixa Biosciences
- Advancing novel CAR-T and vaccine therapies for cancer with strong financial stability.ANIX
Corporate presentation - Net loss narrowed, cash remains strong, and clinical programs advance in cancer vaccines and CAR-T.ANIXQ3 2026
- Net loss narrowed and liquidity remains strong as clinical programs advance in cancer therapies.ANIXQ2 2026
- Advancing innovative cancer therapies with strong clinical data and a capital-efficient strategy.ANIXCorporate presentation
- Innovative cancer therapies and vaccines advance with strong financials and key clinical milestones.ANIXCorporate presentation
- Promising clinical progress and lean strategy set up key data catalysts in the next 12–18 months.ANIXWater Tower Research Insights Conference
- Board actions approved; clinical programs advance with strong financial discipline and 2026 goals.ANIXAGM 2026
- Innovative cancer therapies and vaccines advance in clinic, supported by strong financials and partnerships.ANIXCorporate presentation
- Advancing first-in-class CAR-T and vaccine therapies for cancer with strong clinical progress.ANIXCorporate presentation
Next Anixa Biosciences earnings date
Q4 202612 Jan, 2027
Anixa Biosciences
Next Anixa Biosciences earnings date
Q4 202612 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Anixa Biosciences Inc is a biotechnology company focused on developing therapies and vaccines for cancer and infectious diseases. The company pursues programs in immunotherapy, cancer vaccines, and antiviral therapies through research partnerships and internal development. Anixa Biosciences operates in the early-stage biotechnology sector. The company is headquartered in San Jose, California, and its shares are listed on the NASDAQ.